Frédéric F. Lehmann

Frédéric F. Lehmann has worked in the medical field since 1990. Frédéric F. began their career as a Research Scientist at Ludwig Cancer Research (Brussels) in 1990, where they conducted research and characterization on genes coding for tumor antigens recognized by human cytolytic T lymphocytes and targets for cancer vaccines. In 1997, they completed their residency in Medical Oncology at the Jules Bordet Cancer Center. From 1999 to 2012, they served as Medical Advisor and Translational Research Unit Coordinator for the European Organisation for Research and Treatment of Cancer (EORTC). In 2003, they joined GSK as Vice President, Head of Early Clinical Development WW, Cancer Immunotherapeutics. In this role, they led the R&D and Early Clinical Development Business Unit (INCUBATOR) for Cancer Immunotherapeutics. In 2013, they were promoted to Vice President, Head Oncology Franchise at Celyad. Most recently, in 2022, they were appointed Chief Medical Officer at Smart Immune.

Frédéric F. Lehmann received their Doctor of Medicine (M.D.) from Université catholique de Louvain in 1990. Frédéric F. then went on to obtain a Master's Degree in Medical Internship (hematological master) from the same university in 1997. Finally, they received a Master's Degree in Medical Oncology from Université libre de Bruxelles in 1999.